New Research Highlights Benefits of Higher-Dose Wegovy for Weight Loss

Recent findings from the STEP UP trial reveal that a higher dose of Wegovy, a popular obesity medication, may lead to faster weight loss and greater fat reduction compared to the standard dose. The study highlights that most weight loss comes from fat rather than muscle, addressing concerns about muscle loss during rapid weight loss. With nearly 27% of participants on the higher dose achieving significant weight loss within 24 weeks, these results could reshape obesity treatment strategies. As demand for effective weight-loss solutions grows, this research emphasizes the importance of not just the amount of weight lost, but the type of weight lost, potentially influencing future obesity medication discussions.

By Narendra Chaudhary May 12, 2026, 17:01 IST

Key Findings on Wegovy's Higher Dose

Recent research presented at the European Congress on Obesity (ECO) indicates that a higher dosage of the popular weight-loss medication Wegovy may accelerate weight loss and promote fat loss over muscle loss. The STEP UP trial conducted by Novo Nordisk revealed that participants receiving a 7.2 mg dose of semaglutide, the active component in Wegovy, experienced more significant and quicker weight loss compared to those on the standard 2.4 mg dose. Notably, the majority of the weight lost was attributed to fat, particularly harmful visceral fat associated with heart disease and diabetes.

Study Insights

The research identified a subset of participants termed “early responders,” who managed to shed at least 15% of their body weight within the initial 24 weeks of treatment. Approximately 27% of individuals on the higher 7.2 mg dose fell into this category, in contrast to around 21% on the lower dose. By the 72-week mark, these early responders had an average weight loss of 27.7%, a figure comparable to results typically seen with certain bariatric surgeries. Even those who did not qualify as early responders achieved clinically significant weight loss, with the 7.2 mg group losing an average of 15.4% of their body weight, compared to 13.2% in the lower-dose group.

Concerns regarding muscle loss during rapid weight loss have been prevalent. However, a secondary analysis utilizing MRI scans of 55 participants showed promising results. Researchers found that 84% of the weight lost was from fat mass, while muscle mass reduction was limited to about 10% from the baseline. Importantly, participants retained their functional muscle strength, as evidenced by tests measuring lower-body strength, including a 30-second sit-to-stand assessment, which showed consistent muscle performance pre- and post-treatment.

Further Insights from MRI Scans

The MRI scans also indicated a reduction of over 30% in visceral abdominal fat, which is closely linked to cardiovascular issues, insulin resistance, and metabolic disorders. Dr. Dror Dicker, an associate clinical professor of Internal Medicine at Tel-Aviv University, emphasized that obesity is a chronic condition requiring lifelong, comprehensive treatment. He noted that while rapid weight loss can indicate better long-term outcomes, those who respond more gradually can still gain significant health advantages from semaglutide therapy.

Executives from Novo Nordisk highlighted these findings as further validation that higher-dose Wegovy could play a crucial role in obesity management moving forward. Emil Kongshøj Larsen, the executive vice president and head of International Operations at Novo Nordisk, stated that the results reinforce the drug's ability to promote fat loss while maintaining muscle function. The STEP UP trial monitored 1,407 adults with obesity over 72 weeks, comparing the effects of semaglutide 7.2 mg, semaglutide 2.4 mg, and a placebo, alongside lifestyle changes. As the global demand for weight-loss medications rises, these findings are expected to fuel discussions about higher-dose obesity treatments, particularly as healthcare providers increasingly prioritize not just the amount of weight lost, but the type of weight lost.